Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189057 · ClinicalTrials.gov registry record · NA
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT02189057: Completed NA study, sponsored by Mayo Clinic.
NCT02189057 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02189057, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
The overall goal of this investigator-initiated trial is to evaluate the treatment outcome of depression utilizing platform algorithm products that can allow rapid identification of pharmacokinetic (PK) and/or pharmacodynamic (PD) genomic variation. This new technology may have the potential to optimize treatment selection by improving response, minimizing unfavorable adverse events / side effects and increasing treatment adherence.
Interventions
- OTHER Treatment as usual
- OTHER AssureRx GeneSight genotyping results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-10-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02189057
The ClinicalTrials.gov registry entry for NCT02189057 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment as usual is the first listed.
NCT02189057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02189057 about?
NCT02189057 is a clinical study titled "A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression". The overall goal of this investigator-initiated trial is to evaluate the treatment outcome of depression utilizing platform algorithm products that can allow rapid identification of pharmacokinetic (PK) and/or pharmacodynamic (PD) genomic variation. This new technology may have the potential to opti...
What is the current status of trial NCT02189057?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2014-11. Estimated completion is 2018-10-19.
What interventions are being tested in trial NCT02189057?
The interventions under investigation include: Treatment as usual (OTHER), AssureRx GeneSight genotyping results (OTHER).
Who is sponsoring clinical trial NCT02189057?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.